scholarly journals High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO

2019 ◽  
Vol 74 (7) ◽  
pp. 2030-2038 ◽  
Author(s):  
Ralph-Sydney Mboumba Bouassa ◽  
Christian Diamant Mossoro-Kpinde ◽  
Jean-Chrysostome Gody ◽  
David Veyer ◽  
Hélène Péré ◽  
...  
Keyword(s):  
Therapeutic Failure ◽  
Strand Transfer ◽  
Second Line ◽  
African Children ◽  
Antiretroviral Drug ◽  
Integrase Strand Transfer Inhibitors ◽  
Drug Regimens ◽  
Hiv 1

scholarly journals Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anna Prats ◽  
Ignacio Martínez-Zalacaín ◽  
Beatriz Mothe ◽  
Eugènia Negredo ◽  
Núria Pérez-Álvarez ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Integrase Inhibitor ◽  
Strand Transfer ◽  
Cognitive Differences ◽  
Integrase Strand Transfer Inhibitors ◽  
Initiation Of Therapy ◽  
Main Component ◽  
Living With Hiv ◽  
The Impact ◽  
Hiv 1

AbstractIntegrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral regimens recommended for treatment of HIV infection. However, little is known about the impact of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial to evaluate the effects of INSTI-based antiretroviral therapy on comprehensive brain outcomes (cognitive, functional, and imaging) according to the time since HIV-1 acquisition. We recruited men living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date of HIV-1 acquisition (n = 12) and > 6 months since estimated date of HIV-1 acquisition (n = 15). We also recruited a group of matched seronegative individuals (n = 15). Assessments were performed at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive functioning was comparable between the arms. At week 48, we did not find cognitive differences between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of HIV-1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex over time, with expected negative repercussions for decision-making tasks.

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen

2020 ◽  
Vol 56 (1) ◽  
pp. 106027
Author(s):  
Maria M. Santoro ◽  
Chiara Fornabaio ◽  
Marina Malena ◽  
Laura Galli ◽  
Andrea Poli ◽  
...  
Keyword(s):  
Strand Transfer ◽  
Integrase Strand Transfer Inhibitors ◽  
Hiv 1

Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients

2016 ◽  
Vol 17 (3) ◽  
pp. 109-113 ◽  
Author(s):  
M. Sayan ◽  
A. Gündüz ◽  
G. Ersöz ◽  
A. İnan ◽  
A. Deveci ◽  
...  
Keyword(s):  
Strand Transfer ◽  
Resistance Mutations ◽  
Integrase Strand Transfer Inhibitors ◽  
Turkish Patients ◽  
Hiv 1

Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors

2020 ◽  
Vol 30 (3) ◽  
pp. 126784 ◽  
Author(s):  
Kevin M. Peese ◽  
B. Narasimhulu Naidu ◽  
Manoj Patel ◽  
Chen Li ◽  
David R. Langley ◽  
...  
Keyword(s):  
Strand Transfer ◽  
Integrase Strand Transfer Inhibitors ◽  
Hiv 1

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

2020 ◽  
Vol 75 (12) ◽  
pp. 3517-3524
Author(s):  
M Casadellà ◽  
J R Santos ◽  
M Noguera-Julian ◽  
R Micán-Rivera ◽  
P Domingo ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Low Frequency ◽  
Transmitted Drug Resistance ◽  
Strand Transfer ◽  
Resistance Mutations ◽  
First Line ◽  
Primary Resistance ◽  
Integrase Strand Transfer Inhibitors ◽  
Virological Outcomes ◽  
Hiv 1

Abstract Background Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted. Objectives We evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016. Methods Pre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%–19% of the virus population were considered to be low-frequency variants. Results From a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants. Conclusions Transmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.

Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors

2013 ◽  
Vol 118 ◽  
pp. 74-82 ◽  
Author(s):  
Mauro Carcelli ◽  
Alessia Bacchi ◽  
Paolo Pelagatti ◽  
Gabriele Rispoli ◽  
Dominga Rogolino ◽  
...  
Keyword(s):  
Strand Transfer ◽  
Arene Complexes ◽  
Integrase Strand Transfer Inhibitors ◽  
Ruthenium Arene ◽  
Hiv 1

Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors

2015 ◽  
Vol 58 (20) ◽  
pp. 8154-8165 ◽  
Author(s):  
Izzat T. Raheem ◽  
Abbas M. Walji ◽  
Daniel Klein ◽  
John M. Sanders ◽  
David A. Powell ◽  
...  
Keyword(s):  
Second Generation ◽  
Strand Transfer ◽  
Integrase Strand Transfer Inhibitors ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document